CORALVILLE, Iowa, Dec. 8 /PRNewswire-FirstCall/ -- Vivakor, Inc. today announced the mechanics for how shareholders of record on December 1, 2009 will receive the dividend of shares of common stock of HealthAmerica, Inc. that was previously approved by Vivakor’s Board of Directors. HealthAmerica is a private Nevada corporation of which Vivakor owned approximately 84% of the outstanding common shares on the record date. The distribution date will be December 9, 2009, and will be conducted as an “upon surrender” distribution. Each Vivakor shareholder will be entitled to receive one share of HealthAmerica common stock for each share of Vivakor common stock beneficially owned on December 1, 2009. The shares of Health America being distributed shall be recorded in the name of each Vivakor shareholder of record on December 1, 2009 as a journal entry with the transfer agent, Integrity Stock Transfer, located in Las Vegas, Nevada. Any shareholder of Vivakor as of the record date, December 1, 2009, may request a certificate directly from the transfer agent, or may simply request a confirmation that a journal entry of the shares with the transfer agent. No other action is required by the Vivakor shareholders to obtain their shares.
Vivakor(TM) is a biomedical/biotechnology company with transdisciplinary research that develops and acquires products in the fields of molecular medicine, electro-optics, biological handling and natural and formulary compounds, that extend or improve life. More information can be found about Vivakor at www.vivakor.com.
HealthAmerica is developing a patented, FDA 510(k) cleared, technology (VIVASlices(TM)) that is expected to enhance the resolution of images resulting from MRI. The underlying algorithm may also be useful in determining blood flow velocity measures in imaged tissues, which would be valuable in accessing areas of blood flow constriction from plaques or other hematologic deposits. This information could help physicians better diagnose, predict and assess stroke and related diseases involving blood flow obstruction.
FORWARD-LOOKING STATEMENTS
CONTACT: Matt Nicosia of Vivakor, Inc., +1-319-625-2172,
mnicosia@vivakor.com
Web site: http://www.vivakor.com/
